About CTI Life Sciences Fund
CTI Life Sciences Fund is a venture capital firm founded in 2006. It is primarily based out of Montreal, Canada. As of Feb 2026, CTI Life Sciences Fund is an active investor, having invested in 33 companies, with 3 new investments in the last 12 months. It primarily invests in Series A round in Canada based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of KainovaTX Overall, CTI Life Sciences Fund portfolio has seen 4 IPOs and 7 acquisitions including key companies like Zymeworks, Vaxcyte and Profound Medical. A lot of funds co-invest with CTI Life Sciences Fund, with names like Fonds de solidarite FTQ sharing a substantial percentage of its portfolio. CTI Life Sciences Fund has team of 8 people including 5 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 4 more
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
CTI Life Sciences Fund's List of Top Investments
CTI Life Sciences Fund has a portfolio of 33 companies. Their most notable investments are in Aeovian Pharmaceuticals and AbilityPharma.Their portfolio spans across Canada, United States, France and 3 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 1 other sectors, across stages such as Series A, Seed and 4 more. Here is the list of top investments by CTI Life Sciences Fund:1. Zymeworks
Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer. The company’s Azymetric and AlbuCORE platforms, and its proprietary ZymeCAD structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications.
Key facts about Zymeworks
- Founded Year: 2003
- Location: Vancouver (Canada)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $146M
- Employee Count: 271 as on Jun 30, 2026
- Investors: Teralys Capital, Celgene and 17 Others
- Latest Funding Round: Post IPO, Dec 26, 2023, $*****
- Highlight: Public
2. Vaxcyte
Developer of vaccines to treat infectious diseases. The company uses the cell-free protein synthesis platform called XpressCFTM along with the company's proprietary knowledge base to design and produce protein carriers and antigens for site-specific conjugation (building blocks of vaccines) for developing antigens and pneumococcal conjugate vaccines (VAS-24). It is also developing vaccines for invasive, pneumococcal diseases, otitis media, strep infections, and periodontitis.
Key facts about Vaxcyte
- Founded Year: 2013
- Location: Foster City (United States)
- Stage: Public
- Total Funding till date: $283M
- Employee Count: 563 as on Jun 30, 2026
- Investors: HTIF, Foresite Capital and 16 Others
- Latest Funding Round: Series D, Apr 03, 2020, $*****
- Highlight: Public
Developer of image guided prostate ablation system for cancer treatment. The company uses proprietary technology and provide TULSA-PRO is an AI-powered, MRI-guided, incision-free robotic ablation system for the ablation of prostate tissue.
Key facts about Profound Medical
- Founded Year: 2008
- Location: Toronto (Canada)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $37.7M
- Employee Count: 186 as on Jun 30, 2026
- Investors: Stifel, FedDev Ontario and 11 Others
- Latest Funding Round: Post IPO, Dec 19, 2025, $*****
- Highlight: Public
4. enGene
EnGene is developing a non-viral gene therapy platform for the delivery of nucleic acid payloads to mucosal tissues. Its flagship platform DDX is a derived chitosan platform delivers DNA and various forms of RNA to broad tissue and disease applications. It has also developed a gut-optimized gene delivery formulation, Gene Pill for Short Bowel Syndrome (SBS). Gene Pill enables the oral delivery of DNA encoding a long-acting GLP-2 analog directly to GIT.
Key facts about enGene
- Founded Year: 1999
- Location: Saint laurent (Canada)
- Stage: Public
- Total Funding till date: $54M
- Employee Count: 151 as on Jun 30, 2026
- Investors: Venrock, Cormorant Asset Management and 15 Others
- Latest Funding Round: Post IPO, Oct 25, 2024, $*****
- Highlight: Public
Developer of GPCR‑targeted immuno‑oncology and inflammation drug candidates. It offers small molecule and antibody therapeutics targeting G protein‑coupled receptors involved in immune suppression and tumor microenvironment modulation. Its proprietary platform supports the identification and validation of novel GPCR targets. Key programs focus on oral EP4 receptor antagonists for solid tumors, Treg‑depleting anti‑CCR8 antibodies, and PAR2 negative allosteric modulators for inflammatory diseases. The pipeline emphasizes precision therapy guided by biomarker strategies, aiming to enhance immune response and address resistance mechanisms in cancer and inflammation.
Key facts about Domain Therapeutics
- Founded Year: 2008
- Location: Strasbourg (France)
- Annual Revenue: €1M - €10M as on Dec 31, 2023
- Stage: Series A
- Total Funding till date: $51.2M
- Employee Count: 36 as on Jun 30, 2026
- Investors: Auriga Partners, Bpifrance and 26 Others
- Latest Funding Round: Series A, May 10, 2022, $*****
- Highlight: Editors' Pick
CTI Life Sciences Fund's Year-on-Year Investment Trends
CTI Life Sciences Fund has invested in 33 companies over the last 19 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 3 investments, while as of Feb 2026, it has made 1 investment in this year. Its most recent first time investment was in KainovaTX and most recent follow-on round was in Epitopea.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 3 | 0 | 3 |
2024 | 1 | 2 | 3 |
2023 | 1 | 1 | 2 |
2022 | 2 | 0 | 2 |
2021 | 0 | 0 | 0 |
2020 | 2 | 1 | 3 |
2019 | 0 | 0 | 0 |
2018 | 0 | 1 | 1 |
2017 | 3 | 2 | 5 |
CTI Life Sciences Fund's Investments by Stage
CTI Life Sciences Fund has made 8 investments in Series A stage with an average round size of $18.1M, 5 investments in Seed stage with an average round size of $13.2M and 5 investments in Series B stage with an average round size of $39.8M.Stage of entry | No. of Investments |
|---|---|
Series A | 8 |
Seed | 5 |
Series B | 5 |
Series C | 4 |
Conventional Debt | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
CTI Life Sciences Fund's Investments by Sector
CTI Life Sciences Fund has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, HealthTech, Sustainability Tech and High Tech. Notably, it has invested in 30 Tech companies, 27 Enterprise (B2B) companies, 8 Software companies and at least 3 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 22 |
Enterprise Applications | 4 |
HealthTech | 3 |
Sustainability Tech | 3 |
High Tech | 2 |
Others | 2 |
Note: We have considered here, only first round of investments
CTI Life Sciences Fund's Investments by Geography
CTI Life Sciences Fund has made most investments in Canada (13), followed by United States where it has made 7 investments.Country | No. of Investments |
|---|---|
Canada | 13 |
United States | 7 |
France | 2 |
Spain | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
CTI Life Sciences Fund's recent investments
CTI Life Sciences Fund has made 1 investments in 2026 so far - KainovaTX.Here are the most recent investments by CTI Life Sciences Fund:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Feb 10, 2026 | Canada | Series B | 4568 | [+8] | |
Nov 18, 2025 | United States | Series B | 6832 | [+8] | |
Sep 2025 | United States | Series B | 7413 | ||
Apr 16, 2025 | United States | Series C | 1812 | [+9] | |
Oct 24, 2024 | United Kingdom | Seed | 8982 | [+8] |
IPOs and Publicly Listed companies in CTI Life Sciences Fund's Portfolio
4 of CTI Life Sciences Fund's portfolio companies have become public. enGene got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Nov 2023 and Vaxcyte got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $774M.Here are CTI Life Sciences Fund's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 01, 2023 | - | - | 1410 | |
Jun 12, 2020 | Jul 23, 2015 | Series A | 4003 | |
May 17, 2017 | - | - | 1038 | |
Apr 28, 2017 | Jun 22, 2009 | Series A | 3433 |
Acquired companies in CTI Life Sciences Fund's Portfolio
7 companies from CTI Life Sciences Fund's portfolio have been acquired. The most recent acquisition was Amolyt Pharma in Mar 2024 by AstraZeneca for $*****.Here are CTI Life Sciences Fund's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 14, 2024 | Jan 06, 2023 | Series C | 1501 | |
May 21, 2023 | - | - | 3119 | |
Oct 09, 2018 | Oct 05, 2012 | Seed | 5764 | |
Jul 11, 2018 | Oct 05, 2017 | Series C | 8098 | |
Jul 12, 2013 | - | - | 6515 |
Team profile of CTI Life Sciences Fund
CTI Life Sciences Fund has a team of 8 members including 5 Partners and 1 Principal located in Canada. CTI Life Sciences Fund's team sits on the board of 1 company.Here is a list of all team members in CTI Life Sciences Fund:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Montreal | - | ||
Partner | Montreal | - | ||
Partner | Toronto | - | ||
Partner | Lorraine | - | ||
Partner | Ottawa | - | - | |
Principal | Toronto | - |
Co-investors of CTI Life Sciences Fund
Over the past 19 years, 182 investors have co-invested in CTI Life Sciences Fund's portfolio companies. This includes funds and angels.
- Invested before CTI Life Sciences Fund: Bpifrance, Novo Holdings and 75 others have invested in rounds before CTI Life Sciences Fund. There are 2 companies where Bpifrance has invested before CTI Life Sciences Fund and 2 companies where Novo Holdings has invested before CTI Life Sciences Fund.
- Top Co-investors of CTI Life Sciences Fund: 70 investors entered a company along with CTI Life Sciences Fund. These include investors like Fonds de solidarite FTQ (6 companies).
- Invested after CTI Life Sciences Fund: A total of 35 investors have invested in CTI Life Sciences Fund's portfolio after their investments. Top Investors include Invest Quebec (3 companies), Fonds de solidarite FTQ (1 company) and Merlin Nexus (1 company).
Recent News related to CTI Life Sciences Fund
•
Kainova Therapeutics Secures $32M CAD to Accelerate Therapy DevelopmentBenzinga•Feb 10, 2026•Invest Quebec, KainovaTX, Turenne Groupe, Schroders Capital and 8 others
•
Aeovian gets $55M for tuberous sclerosis complex, to explore prospects in obesityEndpoints•Dec 16, 2025•Aeovian Pharmaceuticals, Hevolution, Sofinnova Investments, CTI Life Sciences Fund and 7 others
•
•
Glycomine raises $115m to advance rare disease therapy into Phase IIb
Pharmaceutical Technology•Apr 16, 2025•Glycomine, CTI Life Sciences Fund, Advent Life Sciences, Novo Holdings and 7 others
•
Glycomine Secures $115M Series C Funding for Rare Disease TreatmentBioSpace•Apr 16, 2025•Glycomine, CTI Life Sciences Fund, Advent Life Sciences, Novo Holdings and 7 others
•
Glycomine Secures $115M in Series C FundingFinSMEs•Apr 16, 2025•Glycomine, CTI Life Sciences Fund, abrdn, Advent Life Sciences and 8 others
•
•
•
DalCor Pharmaceuticals Closes USD80M Series D FinancingFinSMEs•Sep 21, 2023•DalCor, Economy And Finance, Invest Quebec, T&B Pharma and 3 others
•
SPAC Forbion European to merge with Canadian biotech enGeneSeeking Alpha•May 18, 2023•Forbion, enGene, BVF Partners, Omega Funds and 7 others
